fMRI task conditions.

<p>fMRI task conditions.</p

Effects of TSD for fMRI and [¹¹C]raclopride PET.

<p><i>p</i> <0.005, extent threshold 10 voxels. A and B are task related fMRI results, showing increased prefrontal and limbic activation respectively, in the conditions (A) positive valence versus baseline and (B) both emotional valences. C is a [¹¹C]raclopride PET image, showing decreased voxel-by-voxel RPM2 binding potential (BP_ND) in nucleus caudatus in <i>n</i> = 8. At the bottom right is the Z-score scale depicted.</p

Effects of total sleep deprivation on saliva cortisol levels.

<p>Individual saliva cortisol curves (grey line) and cortisol mean value (nmol/L) per Tx sampling point (solid line). Day 1 shows baseline cortisol sampling at T1-T7, day 2 shows effects of one night of total sleep deprivation on cortisol levels at T8-T14. T1, 2 and 3 comprise the cortisol awakening response (CAR). T8, 9 and 10 are sampled at identical time points the following day. T5 and T12 are sampled at 14.00hr, T6 and T13 at 17.00hr and T7 and T14 at 23.00hr. <i>p</i> values show effects of TSD, # <i>p</i> = 0.016.</p

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

<div><p>3′-deoxy-3′-[¹⁸F]fluoro-L-thymidine (FLT) and 2′-deoxy-2′-[¹⁸F]fluoro-D-glucose (FDG) are used to visualize proliferative and metabolic activity of tumors. In this study we aimed at evaluating the prognostic value of FLT and FDG uptake measured by positron emission tomography (PET) in patients with metastatic non-small cell lung cancer (NSCLC) prior to systemic therapy with erlotinib. FLT and FDG maximum standardized uptake (SUVmax) values per patient were analyzed in 40 chemotherapy naive patients with advanced NSCLC (stage IV) before treatment with erlotinib. Prior therapy median SUVmax was 6.6 for FDG and 3.0 for FLT, respectively. In univariate analysis, patients with an FDG SUVmax <6.6 had a significantly better overall survival (16.3 months [95% confidence interval [CI] 7.1–25.4 months]) compared to patients with an FDG SUVmax ≥6.6 (3.1 months [95% CI 0.6–5.5 months]) (p<0.001, log rank). Similarly, low FLT uptake (SUVmax <3.0) was associated with significantly longer survival (10.3 months (0–23.3 months, 95% CI) compared to high FLT uptake (3.4 months (0–8.1 months, 95% CI) (p = 0.027). The independent prognostic value of baseline FDG uptake was demonstrated in multivariate analysis (p = 0.05, Cox regression). These data suggest that baseline SUVmax values for both FDG and FLT PET might be further developed as markers for prognostic stratification of patients in advanced NSCLC treated with tyrosine kinase inhibitors (TKI) directed against the epidermal growth factor receptor (EGFR).</p> <h3>Trial Registration</h3><p>Clinicaltrials.gov, Identifier: <a href="http://clinicaltrials.gov/ct2/show/NCT00568841">NCT00568841</a></p> </div

Individual patient characteristics and PET results.

<p>Individual patient characteristics and PET results.</p

Kaplan Meier curves showing overall survival depending on SUVmax values.

<p>A) Overall survival of patients with high (>6.7; grey) or low (<6.7; red) baseline SUVmax in FDG-PET. (B) Overall survival of patients with high (>3; grey) or low (<3; red) baseline SUVmax in FLT-PET.</p

Example of two patients with low and high baseline uptake of FDG and FLT.

<p>The patient shown in figure A with low uptake is a 66-year old female patient who had an overall survival of 21.3 months, whereas the patient in B with a high uptake is a 56-year old female patient with an overall survival of only 1.5 months. In both cases, the respective most active lesion was chosen for assessment.</p

Correlation of the EGFR mutational status with Ki-67 staining in %.

<p>Correlation of the EGFR mutational status with Ki-67 staining in %.</p

Patient characteristics.

<p>Patient characteristics.</p